Rapport Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a)None.
(b) During the quarter ended December 31, 2024, the following directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted certain trading plans intended to satisfy the requirements of Rule 10b5-1(c):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Cheryl Gault(Chief Operating Officer) | Adoption (December 11, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | Approximately 8 months | 10,000 |
| Abraham Ceesay (Chief Executive Officer) | Adoption (December 12, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | Approximately 11 months | 131,000 (1) |
|---|---|---|---|---|---|
| David Bredt(Chief Scientific Officer) | Adoption (December 12, 2024) | Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | Approximately 11 months | 102,000 |
(1) Consists of 70,000 shares held by Mr. Ceesay and 61,000 shares held by The Dorothy Ceesay Irrevocable Trust.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.